Abstract
Neuropeptide Y (NPY) potentiates the contractile response of the rat caudal artery to adrenergic nerve stimulation in-vitro. The NPY Y 1 selective antagonist BIBP3226 ((R)-N 2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-argininamide), inhibited the vascular effects of NPY in rat caudal artery preparations in-vitro (IC 50 = 126 nM). BIBP3226 also inhibited the effects of the selective Y 1 agonist [Leu 31,Pro 34]NPY and completely abolished the effects of avian pancreatic polypeptide that was shown to be capable of potentiating neurogenic vasoconstriction in this preparation. These effects were reversible and are most likely mediated by the Y 1 receptor subtype since we failed to observe any functional evidence of a Y 2 receptor subtype in rat caudal artery. The caudal artery provides a useful functional assay for pharmacological analysis of NPY and NPY antagonists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
